s0122212
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.500
- ALLOGRAFT_REJECTION+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
- PROTEIN_SECRETION+0.400
- E2F_TARGETS+0.300
- G2M_CHECKPOINT+0.300
- SPERMATOGENESIS+0.200
- UNFOLDED_PROTEIN_RESPONSE+0.200
- ANDROGEN_RESPONSE+0.100
- COMPLEMENT+0.100
Top 10 suppressed
- ANGIOGENESIS-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- APICAL_SURFACE-0.400
- MYOGENESIS-0.400
- TGF_BETA_SIGNALING-0.400
- ADIPOGENESIS-0.300
- APICAL_JUNCTION-0.300
- COAGULATION-0.300
- ESTROGEN_RESPONSE_EARLY-0.300
- ESTROGEN_RESPONSE_LATE-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR4195655 | — | — | 0.894 |
| 2 | SRR2016949 | — | — | 0.871 |
| 3 | aMVAC.P_006_TURBT_S224 | — | — | 0.862 |
| 4 | SRR4195675 | — | — | 0.847 |
| 5 | TCGA-55-A4DF-01A-11R-A24H-07 | — | cohortA3 | 0.842 |
| 6 | GSM6454730 | — | D | 0.826 |
| 7 | MBCProject_1542_T2_RNA | — | D | 0.824 |
| 8 | SRR8518291 | — | D | 0.823 |
| 9 | TCGA-DK-A3IV-01A-22R-A21D-07 | — | — | 0.815 |
| 10 | 1b0a23c2-785d-4a14-b673-86c97ceff401 | — | — | 0.814 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.100 | Inavolisib | — uncovered |